Sayantan Ray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sayantan Ray has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Jui Chakraborty
CSIR-Central Glass and Ceramic Research Institute
6 shared publications Suman Saha
CSIR-Central Glass and Ceramic Research Institute
6 shared publicationsBiswanath Sa
4 shared publicationsJui Chakraborty
3 shared publications- Rituparna Acharya
Institute of Management Study Kolkata,India
3 shared publications Swapankumar Ghosh
2 shared publications
Latest Publications
- 11 October 2017
- Published by Springer Nature
- p. 419-451
Nanoparticulate Immunotherapy: An Intelligent Way to Tailor Make Our Defense System
- 11 October 2017
- Published by Springer Nature
- p. 419-451
Nanoparticulate Immunotherapy: An Intelligent Way to Tailor Make Our Defense System
- 1 June 2017
- Published by American Scientific Publishers in Advanced Science, Engineering and Medicine
- Vol. 9 (6) , 469-477
Development of a Sustained Release Solid Dosage Formulation for Delivery of a Poorly Water Soluble Hypoglycemic Agent Using Novel Ceramic Vehicle
Gliclazide is a second-generation sulfonylurea compound used as a prescription medicine in the treatment of non insulin dependent diabetes mellitus (NIDDM) or type II diabetes. As a consequence of the poor aqueous solubility, the therapeutic efficacy of the drug in oral dosage form suffers from major drawbacks, e.g., inter-individual variable bioavailability. To overcome the same, various extended/sustained release (SR, matrix mediated) oral dosage formulations have been attempted and in the present communication, we report the use of a biocompatible and biodegradable anionic clay, known as Mg–Al layered double hydroxides (LDHs) to encapsulate the gliclazide drug by ex situ anion exchange process, to form LDH-GLZSR sustained release tablet, known as LDH-GLZSR. It was characterized structurally and compositionally by various analytical techniques. The LDH-GLZSR tablet was manufactured by direct compression method, followed by using microcrystalline cellulose as binder, crospovidone as disintegrator and magnesium stearate as lubricant. Different post formulation parameters of LDH-GLZSR tablets were evaluated and in vitro dissolution study was carried out in two pH conditions (1.2 for stomach and 6.8 for colon), comparing the same to a market available polymer based SR formulation (tablet) of the same drug, named as GLZ-SR to estimate the suitability of the former for a similar use.
- 1 June 2017
- Published by American Scientific Publishers in Advanced Science, Engineering and Medicine
- Vol. 9 (6) , 469-477
Development of a Sustained Release Solid Dosage Formulation for Delivery of a Poorly Water Soluble Hypoglycemic Agent Using Novel Ceramic Vehicle
Gliclazide is a second-generation sulfonylurea compound used as a prescription medicine in the treatment of non insulin dependent diabetes mellitus (NIDDM) or type II diabetes. As a consequence of the poor aqueous solubility, the therapeutic efficacy of the drug in oral dosage form suffers from major drawbacks, e.g., inter-individual variable bioavailability. To overcome the same, various extended/sustained release (SR, matrix mediated) oral dosage formulations have been attempted and in the present communication, we report the use of a biocompatible and biodegradable anionic clay, known as Mg–Al layered double hydroxides (LDHs) to encapsulate the gliclazide drug by ex situ anion exchange process, to form LDH-GLZSR sustained release tablet, known as LDH-GLZSR. It was characterized structurally and compositionally by various analytical techniques. The LDH-GLZSR tablet was manufactured by direct compression method, followed by using microcrystalline cellulose as binder, crospovidone as disintegrator and magnesium stearate as lubricant. Different post formulation parameters of LDH-GLZSR tablets were evaluated and in vitro dissolution study was carried out in two pH conditions (1.2 for stomach and 6.8 for colon), comparing the same to a market available polymer based SR formulation (tablet) of the same drug, named as GLZ-SR to estimate the suitability of the former for a similar use.
- 3 January 2017
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 7 (2) , 259-275
In vivo pharmacological evaluation and efficacy study of methotrexate-encapsulated polymer-coated layered double hydroxide nanoparticles for possible application in the treatment of osteosarcoma
Considering the existing drawbacks of methotrexate (MTX) with respect to its solubility and toxicity, we incorporated it in a nanoceramic matrix, Mg–Al-layered double hydroxide (LDH) to form LDH-MTX nanoparticles, and the same was in turn encapsulated in a nontoxic and biodegradable polymer, poly (D,L-lactide-co-glycolide) (PLGA), to arrest the initial burst release and dose-dumping-related toxicity, already reported by our group. Our present study was designed to evaluate the pharmacokinetics, tissue distribution, survival rate of the test animals, and antitumor efficacy of the PLGA-LDH-MTX nanoparticles and its counterpart without LDH, PLGA-MTX nanoparticles compared with bare MTX. The median lethal dose (LD50) of the former was higher, compared with bare MTX, using Balb/c nude mice, indicating it to be completely safe for use. Also, a comparative pharmacokinetic and antitumour efficacy study using MTX, PLGA-MTX, and PLGA-LDH-MTX nanoparticles in osteosarcoma-induced Balb/c nude mice in vivo demonstrated superiority of PLGA-LDH-MTX as compared to PLGA-MTX and bare MTX. The results suggest that PLGA-LDH-MTX nanoparticles might exhibit potential advantages over the present-day chemotherapy over bare MTX, for the possibility of treatment of osteosarcoma.
- 3 January 2017
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 7 (2) , 259-275
In vivo pharmacological evaluation and efficacy study of methotrexate-encapsulated polymer-coated layered double hydroxide nanoparticles for possible application in the treatment of osteosarcoma
Considering the existing drawbacks of methotrexate (MTX) with respect to its solubility and toxicity, we incorporated it in a nanoceramic matrix, Mg–Al-layered double hydroxide (LDH) to form LDH-MTX nanoparticles, and the same was in turn encapsulated in a nontoxic and biodegradable polymer, poly (D,L-lactide-co-glycolide) (PLGA), to arrest the initial burst release and dose-dumping-related toxicity, already reported by our group. Our present study was designed to evaluate the pharmacokinetics, tissue distribution, survival rate of the test animals, and antitumor efficacy of the PLGA-LDH-MTX nanoparticles and its counterpart without LDH, PLGA-MTX nanoparticles compared with bare MTX. The median lethal dose (LD50) of the former was higher, compared with bare MTX, using Balb/c nude mice, indicating it to be completely safe for use. Also, a comparative pharmacokinetic and antitumour efficacy study using MTX, PLGA-MTX, and PLGA-LDH-MTX nanoparticles in osteosarcoma-induced Balb/c nude mice in vivo demonstrated superiority of PLGA-LDH-MTX as compared to PLGA-MTX and bare MTX. The results suggest that PLGA-LDH-MTX nanoparticles might exhibit potential advantages over the present-day chemotherapy over bare MTX, for the possibility of treatment of osteosarcoma.
- 1 January 2017
- Published by Elsevier in Applied Clay Science
- Vol. 135, 493-509
Magnesium, zinc and calcium aluminium layered double hydroxide-drug nanohybrids: A comprehensive study
- 1 January 2017
- Published by Elsevier in Applied Clay Science
- Vol. 135, 493-509
Magnesium, zinc and calcium aluminium layered double hydroxide-drug nanohybrids: A comprehensive study
- 20 September 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (92) , 89467-89483
Role of a nitrogenous bisphosphonate (local delivery) incorporated vitreous coating (with/without polymer) on surgical grade SS316L implant material to improve fixation at the damaged tissue site
Nitrogenous bisphosphonate, alendronate sodium (AS) was incorporated in the bilayered (layer 1, impervious and layer 2, porous) vitreous coating of phosphate free bioactive glass (PFBG) coated on surgical grade SS316L blocks, for a possible treatment of peri implant bone loss as a consequence of implantation at the fracture site, by local delivery. The presence of the drug in the pores (dia: 0.5–8 μm) of layer 2 was confirmed by SEM-EDX analysis. To control the drug release and thereby improve the efficacy of the system, the drug loaded vitreous layer was further coated with a thin layer (thickness: 1–2 μm) of poly(D,L-lactic-co-glycolic acid, PLGA). Irrespective of the polymer coating, the drug release kinetics were diffusion controlled from a porous matrix and the drug was fluorescently tagged and internalized by mouse macrophage cells (RAW 264.7) which was analysed by flow cytometry (FACS), followed by assessing the time dependent inhibitory action of the above drug on the osteoclastogenic cytokine, TNFα of the RAW 264.7 cell line, demonstrated by ELISA (enzyme-linked immunosorbent assay), and the same was confirmed and correlated by the time dependent growth inhibition of the transfected (from RAW 264.7 cell line) osteoclast cells by quantitative TRAP staining. The in vivo animal trial exhibited angiogenesis and initiation of bone remodelling in a New Zealand white rabbit model during the study period of 90 days, with or without a polymer coating and this mutual comparison has been highlighted in all the in vitro characterisation results too. In summary, an attempt has been made herewith to establish the versatility of alendronate sodium to promote improved fixation of the PFBG coated SS316L load bearing implants at the damaged tissue site, exhibiting an overall better response in the case of its polymer coated counterpart via an extended release profile, leading to a higher possibility of bone regeneration.
- 20 September 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (92) , 89467-89483
Role of a nitrogenous bisphosphonate (local delivery) incorporated vitreous coating (with/without polymer) on surgical grade SS316L implant material to improve fixation at the damaged tissue site
Nitrogenous bisphosphonate, alendronate sodium (AS) was incorporated in the bilayered (layer 1, impervious and layer 2, porous) vitreous coating of phosphate free bioactive glass (PFBG) coated on surgical grade SS316L blocks, for a possible treatment of peri implant bone loss as a consequence of implantation at the fracture site, by local delivery. The presence of the drug in the pores (dia: 0.5–8 μm) of layer 2 was confirmed by SEM-EDX analysis. To control the drug release and thereby improve the efficacy of the system, the drug loaded vitreous layer was further coated with a thin layer (thickness: 1–2 μm) of poly(D,L-lactic-co-glycolic acid, PLGA). Irrespective of the polymer coating, the drug release kinetics were diffusion controlled from a porous matrix and the drug was fluorescently tagged and internalized by mouse macrophage cells (RAW 264.7) which was analysed by flow cytometry (FACS), followed by assessing the time dependent inhibitory action of the above drug on the osteoclastogenic cytokine, TNFα of the RAW 264.7 cell line, demonstrated by ELISA (enzyme-linked immunosorbent assay), and the same was confirmed and correlated by the time dependent growth inhibition of the transfected (from RAW 264.7 cell line) osteoclast cells by quantitative TRAP staining. The in vivo animal trial exhibited angiogenesis and initiation of bone remodelling in a New Zealand white rabbit model during the study period of 90 days, with or without a polymer coating and this mutual comparison has been highlighted in all the in vitro characterisation results too. In summary, an attempt has been made herewith to establish the versatility of alendronate sodium to promote improved fixation of the PFBG coated SS316L load bearing implants at the damaged tissue site, exhibiting an overall better response in the case of its polymer coated counterpart via an extended release profile, leading to a higher possibility of bone regeneration.
- 21 June 2016
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 45 (5) , 944-954
Development of bicalutamide-loaded PLGA nanoparticles: preparation, characterization and in-vitro evaluation for the treatment of prostate cancer
In this study we report the development and optimization of poly (D, L-lactide-co-glycolide) (PLGA) polymer encapsulated poorly aqueous soluble nonsteroidal antiandrogen drug bicalutamide, to develop a sustained release formulation for the treatment of prostate cancer. The bicalutamide-loaded PLGA nanoparticles were prepared by single emulsion (O/W) solvent evaporation method, and different process parameters like polymer concentration in the organic phase, surfactant concentration in aqueous phase and centrifugation speed for separation of nanoparticles were evaluated to optimize the drug-loaded nanoparticles. The optimum formulation of bicalutamide-loaded PLGA nanoparticles characterized extensively by different analytical techniques like laser light scattering to determine average particle size and size distribution, scanning electron microscopy (SEM) for surface morphology, powder X-ray diffraction (PXRD) for surface chemistry and differential scanning calorimetry (DSC) for thermogram properties. Significant decrease of crystallinity of bicalutamide confirms entrapment of the drug within the PLGA polymer matrix. Further, the drug encapsulation efficiency (EE) and in vitro drug release profile were measured by high-performance liquid chromatography and UV-spectrophotometry. In vitro drug release exhibited biphasic pattern with initial burst release followed by slow and continuous release up to 5 days. Optimum formulation of bicalutamide-loaded PLGA nanoparticles shows significant anti-tumor activity over prostate cancer cell lines (DU 145). The newly developed optimum formulation nanoparticles could be useful for sustained release delivery of bicalutamide.
- 21 June 2016
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 45 (5) , 944-954
Development of bicalutamide-loaded PLGA nanoparticles: preparation, characterization and in-vitro evaluation for the treatment of prostate cancer
In this study we report the development and optimization of poly (D, L-lactide-co-glycolide) (PLGA) polymer encapsulated poorly aqueous soluble nonsteroidal antiandrogen drug bicalutamide, to develop a sustained release formulation for the treatment of prostate cancer. The bicalutamide-loaded PLGA nanoparticles were prepared by single emulsion (O/W) solvent evaporation method, and different process parameters like polymer concentration in the organic phase, surfactant concentration in aqueous phase and centrifugation speed for separation of nanoparticles were evaluated to optimize the drug-loaded nanoparticles. The optimum formulation of bicalutamide-loaded PLGA nanoparticles characterized extensively by different analytical techniques like laser light scattering to determine average particle size and size distribution, scanning electron microscopy (SEM) for surface morphology, powder X-ray diffraction (PXRD) for surface chemistry and differential scanning calorimetry (DSC) for thermogram properties. Significant decrease of crystallinity of bicalutamide confirms entrapment of the drug within the PLGA polymer matrix. Further, the drug encapsulation efficiency (EE) and in vitro drug release profile were measured by high-performance liquid chromatography and UV-spectrophotometry. In vitro drug release exhibited biphasic pattern with initial burst release followed by slow and continuous release up to 5 days. Optimum formulation of bicalutamide-loaded PLGA nanoparticles shows significant anti-tumor activity over prostate cancer cell lines (DU 145). The newly developed optimum formulation nanoparticles could be useful for sustained release delivery of bicalutamide.
- 1 June 2016
- Published by American Scientific Publishers in Advanced Science, Engineering and Medicine
- Vol. 8 (6) , 450-459
Methotrexate Intercalated CaAl Layered Double Hydroxide Nanohybrid for Drug Delivery
The synthesis of CaAl-layered double hydroxide (CaAl-LDH) nanoparticles has been reported as a carrier of anticancerous drug, methotrexate (MTX) that has been intercalated into the LDH interlayer space by simple anion exchange technique. The insertion of the calcium ion, having larger ionic radius (114 pm) compared to the magnesium ion (86 pm) in the octahedral hole of the brucite layer in the previously reported MgAlLDH system, generated lattice strain, calculated by the well known Scherrer formula in XRD study. On intercalation of the drug molecule in the inter layer space, this strain as above was reduced substantially and an increase in its basal spacing was obtained. This was supported by the high resolution transmission electron microscopy data that exhibited a substantial enhancement in the interlayer spacing of LDH-MTX by 10.46 Å (8.7 Å in pristine LDH to 19.16 Å in LDH-MTX). Further, increase in the decomposition temperature of the drug molecule from 290 °C to 380 °C indicate enhanced thermal stability of the drug molecule, being encapsulated in the LDH nanovehicle, as exhibited by the thermogravimetry analysis. The sustained release of the MTX drug for a prolonged period of 60 h, in phosphate buffer saline (PBS) at pH 7.4 followed Koresmeyers and Peppas model release kinetics via anomalous mechanism. The in vitro cytotoxicity study of LDH-MTX nanohybrid was carried out using MG-63 human osteosarcoma cell line, as per standard protocol, that exhibited inhibition of the cancer cell proliferation approximately two times for LDH-MTX compared to the MTX drug alone. To the best of our knowledge, this is the first ever report of the use of CaAl-LDH as carrier for delivery of a toxic anticancer drug, methotrexate.
- 1 June 2016
- Published by American Scientific Publishers in Advanced Science, Engineering and Medicine
- Vol. 8 (6) , 450-459
Methotrexate Intercalated CaAl Layered Double Hydroxide Nanohybrid for Drug Delivery
The synthesis of CaAl-layered double hydroxide (CaAl-LDH) nanoparticles has been reported as a carrier of anticancerous drug, methotrexate (MTX) that has been intercalated into the LDH interlayer space by simple anion exchange technique. The insertion of the calcium ion, having larger ionic radius (114 pm) compared to the magnesium ion (86 pm) in the octahedral hole of the brucite layer in the previously reported MgAlLDH system, generated lattice strain, calculated by the well known Scherrer formula in XRD study. On intercalation of the drug molecule in the inter layer space, this strain as above was reduced substantially and an increase in its basal spacing was obtained. This was supported by the high resolution transmission electron microscopy data that exhibited a substantial enhancement in the interlayer spacing of LDH-MTX by 10.46 Å (8.7 Å in pristine LDH to 19.16 Å in LDH-MTX). Further, increase in the decomposition temperature of the drug molecule from 290 °C to 380 °C indicate enhanced thermal stability of the drug molecule, being encapsulated in the LDH nanovehicle, as exhibited by the thermogravimetry analysis. The sustained release of the MTX drug for a prolonged period of 60 h, in phosphate buffer saline (PBS) at pH 7.4 followed Koresmeyers and Peppas model release kinetics via anomalous mechanism. The in vitro cytotoxicity study of LDH-MTX nanohybrid was carried out using MG-63 human osteosarcoma cell line, as per standard protocol, that exhibited inhibition of the cancer cell proliferation approximately two times for LDH-MTX compared to the MTX drug alone. To the best of our knowledge, this is the first ever report of the use of CaAl-LDH as carrier for delivery of a toxic anticancer drug, methotrexate.
- 9 November 2015
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (124) , 102574-102592
Optimization of the process parameters for the fabrication of a polymer coated layered double hydroxide-methotrexate nanohybrid for the possible treatment of osteosarcoma
The optimization is reported of various process parameters for the development of poly(lactic-co-glycolic acid, PLGA) coating on Mg–Al layered double hydroxide (LDH) nanoparticles intercalated with the anticancer drug methotrexate (MTX). Both double and single emulsion-solvent evaporation techniques were adapted to synthesize the PLGA coated, MTX drug loaded nanoparticles as above, with and without LDH. While keeping some of the process parameters constant, the homogenization speed, concentration of PLGA, LDH-MTX, MTX and surfactants, aqueous and organic phase volume involved in the synthesis of the PLGA-MTX and PLGA-LDH-MTX nanoparticles, were varied and evaluated to obtain the desired particle size range and drug entrapment efficiency for specific use. The optimized and a few selected unoptimized nanoparticles were further assessed for in vitro drug release kinetics and time and dose dependent in vitro cell viability bioassay, in vitro MTX uptake study using human osteosarcoma, MG-63 cell line. The in vivo pharmacokinetic study demonstrated the much higher therapeutic efficacy of the optimized PLGA-LDH-MTX and PLGA-MTX nanoparticles in terms of the enhanced half life of the drug and the slow clearance rate compared to those of the bare MTX drug.
- 9 November 2015
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (124) , 102574-102592
Optimization of the process parameters for the fabrication of a polymer coated layered double hydroxide-methotrexate nanohybrid for the possible treatment of osteosarcoma
The optimization is reported of various process parameters for the development of poly(lactic-co-glycolic acid, PLGA) coating on Mg–Al layered double hydroxide (LDH) nanoparticles intercalated with the anticancer drug methotrexate (MTX). Both double and single emulsion-solvent evaporation techniques were adapted to synthesize the PLGA coated, MTX drug loaded nanoparticles as above, with and without LDH. While keeping some of the process parameters constant, the homogenization speed, concentration of PLGA, LDH-MTX, MTX and surfactants, aqueous and organic phase volume involved in the synthesis of the PLGA-MTX and PLGA-LDH-MTX nanoparticles, were varied and evaluated to obtain the desired particle size range and drug entrapment efficiency for specific use. The optimized and a few selected unoptimized nanoparticles were further assessed for in vitro drug release kinetics and time and dose dependent in vitro cell viability bioassay, in vitro MTX uptake study using human osteosarcoma, MG-63 cell line. The in vivo pharmacokinetic study demonstrated the much higher therapeutic efficacy of the optimized PLGA-LDH-MTX and PLGA-MTX nanoparticles in terms of the enhanced half life of the drug and the slow clearance rate compared to those of the bare MTX drug.
- 14 August 2015
- Published by Springer Nature in Journal of Pharmaceutical Investigation
- Vol. 45 (6) , 593-600
Formulation, development and optimization of mouth dissolving tablets of Rizatriptan benzoate
- 14 August 2015
- Published by Springer Nature in Journal of Pharmaceutical Investigation
- Vol. 45 (6) , 593-600
Formulation, development and optimization of mouth dissolving tablets of Rizatriptan benzoate
- 22 April 2015
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (49) , 39482-39494
pH dependent chemical stability and release of methotrexate from a novel nanoceramic carrier
Considering the pH dependent chemical stability of anticancer drug methotrexate (MTX), the present communication reports a new approach for intercalation of the same in a nanoceramic vehicle, magnesium aluminium layered double hydroxide (LDH), by ex situ anion exchange method at pH 7.00, using 0.3 M ammonium acetate solution for dissolution of the drug. This simple method ensures maximum stability of the drug at the above said pH, with no degradation byproduct (e.g., N10-methyl folic acid formed due to alkaline hydrolysis) under the given experimental conditions, compared to the similar approach, using 0.1 M sodium hydroxide solution, reported in our earlier work. Importantly, the above method leads to an enhanced drug loading of 32.3 wt%, compared to our previous reports. The cumulative release profile of MTX from LDH–MTX formulation in phosphate buffer saline (PBS) at pH 7.4 exhibited burst release initially which was taken care of by imparting a unique coating of poly(D,L-lactide-co-glycolide, PLGA) on the LDH–MTX nanostructure that reduces the toxicity due to local accumulation. Hence, the superiority of the above for use in cancer chemotherapy, over the conventional drug–polymer system has been established w.r.t the drug release profile and a possible hypothesis of the same has been suggested. The half maximal inhibitory concentration (IC50) of the MTX drug used in this study has been determined and the same has been used to estimate the time dependent (24, 48, 72 and 96 h) efficacy of the MTX loaded samples with/without polymer coating, on human colon tumour cells (HCT-116).
- 22 April 2015
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (49) , 39482-39494
pH dependent chemical stability and release of methotrexate from a novel nanoceramic carrier
Considering the pH dependent chemical stability of anticancer drug methotrexate (MTX), the present communication reports a new approach for intercalation of the same in a nanoceramic vehicle, magnesium aluminium layered double hydroxide (LDH), by ex situ anion exchange method at pH 7.00, using 0.3 M ammonium acetate solution for dissolution of the drug. This simple method ensures maximum stability of the drug at the above said pH, with no degradation byproduct (e.g., N10-methyl folic acid formed due to alkaline hydrolysis) under the given experimental conditions, compared to the similar approach, using 0.1 M sodium hydroxide solution, reported in our earlier work. Importantly, the above method leads to an enhanced drug loading of 32.3 wt%, compared to our previous reports. The cumulative release profile of MTX from LDH–MTX formulation in phosphate buffer saline (PBS) at pH 7.4 exhibited burst release initially which was taken care of by imparting a unique coating of poly(D,L-lactide-co-glycolide, PLGA) on the LDH–MTX nanostructure that reduces the toxicity due to local accumulation. Hence, the superiority of the above for use in cancer chemotherapy, over the conventional drug–polymer system has been established w.r.t the drug release profile and a possible hypothesis of the same has been suggested. The half maximal inhibitory concentration (IC50) of the MTX drug used in this study has been determined and the same has been used to estimate the time dependent (24, 48, 72 and 96 h) efficacy of the MTX loaded samples with/without polymer coating, on human colon tumour cells (HCT-116).